secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLARGO, INC. (BLGO)
CIK:        0000880242
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001437749-26-007044
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLargo 2025 revenue falls 56% to $7.8M; net loss widens to $15.2M
-------------------------------------------------------------------

- Total revenue dropped to $7.8M from $17.8M in 2024 due to termination of largest customer's license.
- Net loss of $15.2M vs. $4.3M in prior year; cash balance $3.9M at year end.
- Engineering services revenue from third parties grew 98% to $2.0M.
- Subsidiary Clyra Medical secured first stocking order for ViaCLYR wound irrigation solution.
- PFAS treatment system installed in New Jersey; PFAS breakthrough featured in Chemical Engineering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/880242/000143774926007044/0001437749-26-007044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/880242/000143774926007044/blgo20260305_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-007044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer